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Classical Hodgkin lymphoma (cHL) is one of 
the most common malignant lymphomas. It is 
characterized by the presence of rare Hodgkin 
and Reed/Sternberg (HRS) cells embedded in 
an extensive inflammatory infiltrate. Constitu-
tive activation of NF-B in HRS cells that tran-
scriptionally regulates expression of multiple 
antiapoptotic factors and proinflammatory cy-
tokines plays a central role in the pathogenesis 
of cHL (1, 2). In a nonstimulated condition, 
NF-B proteins are rendered inactive by bind-
ing to inhibitors of NF-B (IBs), which se-
quester them in the cytoplasm. Stimulation of 
multiple receptors activates the IB kinase 
(IKK) complex that phosphorylates IB at two 
specific serine residues, followed by its ubiqui-
tination and proteasomal degradation, thereby 
releasing NF-B proteins and allowing their 
nuclear translocation (3). Recently, two studies 
provided further insights into the molecular 
mechanisms  of  IKK  activation  upon  TNF 
stimulation (4, 5). Activation of the IKK com-
plex and subsequent NF-B activation requires 
Lys63  polyubiquitination  of  RIP1,  a  kinase 
that is recruited to the receptor upon TNF sti-
mulation. IKK- (NF-B essential modulator), 
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Proliferation and survival of Hodgkin and Reed/Sternberg (HRS) cells, the malignant cells of 
classical Hodgkin lymphoma (cHL), are dependent on constitutive activation of nuclear 
factor B (NF-B). NF-B activation through various stimuli is negatively regulated by the 
zinc finger protein A20. To determine whether A20 contributes to the pathogenesis of cHL, 
we sequenced TNFAIP3, encoding A20, in HL cell lines and laser-microdissected HRS cells 
from cHL biopsies. We detected somatic mutations in 16 out of 36 cHLs (44%), including 
missense mutations in 2 out of 16 Epstein-Barr virus–positive (EBV+) cHLs and a missense 
mutation, nonsense mutations, and frameshift-causing insertions or deletions in 14 out of 
20 EBV cHLs. In most mutated cases, both TNFAIP3 alleles were inactivated, including 
frequent chromosomal deletions of TNFAIP3. Reconstitution of wild-type TNFAIP3 in A20-
deficient cHL cell lines revealed a significant decrease in transcripts of selected NF-B 
target genes and caused cytotoxicity. Extending the mutation analysis to primary mediasti-
nal B cell lymphoma (PMBL), another lymphoma with constitutive NF-B activity, revealed 
destructive mutations in 5 out of 14 PMBLs (36%). This report identifies TNFAIP3 (A20), a 
key regulator of NF-B activity, as a novel tumor suppressor gene in cHL and PMBL. The 
significantly higher frequency of TNFAIP3 mutations in EBV than EBV+ cHL suggests 
complementing functions of TNFAIP3 inactivation and EBV infection in cHL pathogenesis.
© 2009 Schmitz et al.  This article is distributed under the terms of an Attribu-
tion–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.jem.org/misc/terms.shtml). After six 
months it is available under a Creative Commons License (Attribution–Noncom-
mercial–Share Alike 3.0 Unported license, as described at http://creativecommons 
.org/licenses/by-nc-sa/3.0/).
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quence of TNFAIP3 after two rounds of seminested amp-
lification. In cases harboring mutations, single HRS and 
nonneoplastic cells were additionally analyzed to confirm clon-
ality and somatic origin of the mutations identified. Chromo-
somal deletions of TNFAIP3 were investigated by interphase 
cytogenetics (i.e., fluorescence in situ hybridization [FISH] or 
the  combined  fluorescence  immunophenotyping  and  inter-
phase cytogenetics [FICTION] technique; Table I, Fig. 2, and 
Table S1). We ascertained somatic, clonal mutations in 12 out 
of 30 cHL cases analyzed. Additionally, 1 out of the 30 cases 
showed a sequence variation that was also present in the re-
spective nontumor cells and, hence, presumably represents a 
polymorphism (Table I and Fig. S2). Including the cell lines, 11 
out of the 16 mutated cases showed deletion of the other allele 
of TNFAIP3. Mutation frequency and mutation patterns dif-
fered significantly (P = 0.002) according to the EBV status of 
the cHL: among 16 EBV+ cHLs, only 2 cases (12.5%) each 
harbored a single somatic missense mutation in the last exon of 
TNFAIP3, whereas 14 out of 20 EBV cHLs showed clonal 
mutations (70%; Fig. 1 B). In 13 out of these 14 mutated EBV 
cHLs, we detected nonsense mutations and insertions or dele-
tions causing frameshifts. In 9 out of the 14 cases carrying mu-
tations generating premature stop codons, both gene copies of 
TNFAIP3 were genetically inactivated as the second alleles   
of the gene were deleted (Table I, Fig. 1 C, and Fig. S2). We 
analyzed 21 additional cHLs by interphase cytogenetics for 
losses in 6q23 and detected signal constellations indicating dele-
tions of TNFAIP3 in 9 cases, confirming the high incidence   
of deletions of the chromosomal locus of TNFAIP3 in cHL 
(Table S1). This is also supported by a recent aCGH study of 
HRS cell–rich cHL cases revealing monoallelic losses of the 
TNFAIP3 locus in 6 out of 10 cases (15).
Inactivating mutation in TNFAIP3 in PMBL
Global gene expression profiling revealed remarkable similari-
ties between the transcriptional profiles of PMBL and cHL 
(16). Furthermore, survival and proliferation of tumor cells of 
PMBL also depend on constitutive NF-B activity (16, 20). 
Hence, we expanded the sequence analysis on primary biopsies 
of PMBL and the PMBL cell line Karpas-1106P, shown to be 
A20 protein negative (Fig. 1 A). TNFAIP3 was sequenced af-
ter one round of amplification from whole-tissue DNA. We 
identified mutations in 5 out of 14 cases (36%), with each mu-
tated case carrying at least one mutation leading to A20 inacti-
vation (Fig. 1 B). In three primary cases in which nontumor 
cells could be isolated by microdissection, the somatic origin of 
the mutations was confirmed. In cases with more than one 
mutation (PMBLs 2 and 3), TNFAIP3 amplicons were further 
cloned to identify allelic distribution of mutations, revealing 
bialleic distribution of the mutations in at least one of the two 
cases (Table II and Fig. S2). Remarkably, deletions in 6q23.3–
6q24.1 have recently been identified by aCGH in 30% of 
PMBLs (21, 22).
Collectively, we identified 16 out of 36 cHLs and 5 out 
of 14 PMBLs harboring somatic mutations in TNFAIP3. 
The majority of mutations represent nonsense mutations and 
the regulatory subunit of the IKK complex, specifically rec-
ognizes these Lys63-linked polyubiquitins attached to RIP1 
and thereby activates IKK and NF-B (4, 5).
A20 is a ubiquitin-modifying enzyme that inhibits NF-B 
activation in succession of TNF receptor– and Toll-like recep-
tor–induced signals (6–8). This enzyme removes Lys63-linked 
ubiquitin chains from RIP1 and adds Lys48 polyubiquitins to 
RIP1, thereby targeting this factor for proteasomal degrada-
tion, thus explaining the molecular mechanism of NF-B in-
hibition by A20 (6). A20 also likely inhibits NF-B activity by 
additional  means,  including  interaction  with  TRAF1  and 
TRAF2 (9).
The TNFAIP3 gene, encoding A20, is located in chromo-
some band 6q23, a region that is frequently deleted in B cell 
lymphomas (10, 11). Recently, studies applying high-resolu-
tion, genome-wide cytogenetic techniques such as array-based 
comparative genomic hybridization (aCGH) or single nucleo-
tide polymorphism (SNP) chip analysis on non-Hodgkin lym-
phoma and cHL reported a region of minimal common loss at 
6q23, including TNFAIP3 (12–15). However, mutations in 
this gene have not been reported in these studies (12–15).
To test whether mutational inactivation of A20 contributes 
to the pathogenesis of cHL and primary mediastinal B cell lym-
phoma (PMBL), another lymphoma with constitutive NF-B 
activity (16), we sequenced TNFAIP3 in these lymphomas, 
and performed functional studies with cHL cell lines.
RESULTS ANd dISCUSSION
Lack of A20 in consequence of mutations in TNFAIP3  
in cHL cell lines
Because the underlying mechanisms of constitutive NF-B 
activity in HL and PMBL are only partly understood (17), we 
analyzed the A20 protein by Western blotting in HL and 
PMBL cell lines (Fig. 1 A). Although TNFAIP3, a direct NF-
B target gene, was reported to be strongly expressed on a 
transcriptional level in virtually all HL cases (18), no A20 pro-
tein was detected in four out of seven HL cell lines analyzed, 
as well as the PMBL cell line Karpas-1106P. DNA sequence 
analysis of the entire coding region of TNFAIP3 revealed a 
nonsense mutation, a duplication, and deletions in the A20 
protein–negative HL cell lines (Table I). Only the mutated 
alleles were identified, explaining the absence of detectable 
protein in the respective cell lines. In accordance with these 
findings, an SNP chip analysis in L-1236, HDLM-2, and 
U-HO1 showed loss of heterozygosity (LOH) in 6q23, in-
cluding the TNFAIP3 locus (Fig. S1). A homozygous dele-
tion in the coding sequence of TNFAIP3 in cell line KM-H2 
was previously reported (19). Because the DEV cell line origi-
nates from nodular lymphocyte–predominant HL, it was ex-
cluded from further analysis.
Inactivating mutation in TNFAIP3 in primary HRS cells  
of EBV cHL
Extending the study to primary biopsies of 30 cHLs, we in-
dividually  laser-microdissected  CD30+  HRS  cells,  pooled 
10–20 cells, and sequenced DNA of the entire coding se-JEM VOL. 206, May 11, 2009  983
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generated lentiviral expression constructs allowing coexpres-
sion of GFP and either A20, IBS32,36A superrepressor or   
luciferase by inserting the Thosea asigna insect virus T2A se-
quence between the coding sequences of the genes. Ribo-
some skipping occurs during translation of the T2A sequence, 
leading to generation of two separate proteins from one tran-
script (23). In the IBS32,36A superrepressor, which served in 
our experiments as a control for NF-B repression, two ser-
ine residues of positions 32 and 36 are replaced by alanines, 
thus preventing the phosphorylation required for proteasomal 
degradation of this NF-B inhibitor (24). To assess A20 ex-
pression levels mediated by lentiviruses and efficient ribo-
some skipping, we analyzed A20 and GFP protein expression 
of isolated GFP-expressing L-1236 cells by Western blotting. 
This revealed the efficiency of ribosome skipping mediated 
deletions or insertions leading to frameshifts (Fig. 1 D). No 
mutation hotspot was identified (Tables I and II; and Fig. 1 D). 
However, most missense mutations are located in the last 
exon of TNFAIP3 coding for most C-terminal A20 zinc fin-
gers. The question of the oncogenic potential of these amino 
acid replacements remains open.
Loss of A20 contributes to constitutive NF-B activity  
in cHL cell lines
Based on this genetic evidence, TNFAIP3 appears to be a tu-
mor suppressor gene in cHL and PMBL. To functionally test 
this hypothesis, we expressed A20 by lentiviral gene transfer 
in cHL cell lines harboring inactivating TNFAIP3 mutations 
(L-1236 and KM-H2) and as a control in a cHL cell line ex-
pressing wild-type A20 (L-428; Fig. 1 A). To this end, we 
Figure 1.  Inactivation of A20 in cHL and PMBL. (A) Mutations in TNFAIP3 correlate with the absence of detectable A20 protein (70 kD) in lym-
phoma cell lines. Immunoblotting using anti-A20 antibody was performed with each 100 µg of whole-cell extracts of PMBL and HL cell lines. -Actin was 
used as loading control. No truncated proteins were detected. (B) Frequency and pattern of TNFAIP3 mutations in PMBL and cHL arranged by EBV status 
(A20 wild-type: cases carrying exclusively wild-type TNFAIP3 sequence; A20 premature stop: cases with destructive mutations [nonsense mutations and 
deletions or insertions causing premature stop codons]; A20 missense: cases with missense mutations). Numbers in brackets indicate the numbers of cases 
analyzed. p-values were calculated using Fisher’s exact test. Case 19 harbors both missense and premature stop, and is depicted among the group with 
premature stop. (C) Graphic representation of allelic distribution of TNFAIP3 mutations of cHL grouped according to EBV status. The columns represent the 
cases, and the rows represent the two alleles. a, the loss of one allele cannot be excluded as cases were not evaluable by FISH and lacked heterozygous  
sequence polymorphisms; b, the case harbors two mutations, but their allelic distribution could not be determined. (D) Schematic representation of location 
of TNFAIP3 mutations translated to A20 protein in cHL and PMBL, as described in Tables I and II. OTU, ovarian tumor domain; ZF, A20 zinc finger domains.984 INACTIVATION OF TNFAIP3 (A20) IN cHL AND PMBL | Schmitz et al.
Table I.  Sequence and gene copy number analysis of TNFAIP3 from cHL cell lines and primary HRS cells
Sample EBV Subtype Nucleotide changea Amino acid changeb LOH/Delc Both alleles 
mutated
Cell lines
  L-591 + NS    
  L-428  NS   +d 
  HDLM-2  NS (T cell origin) Dupl. 586–614  Frameshift aa 174 +d +
  KM-H2  NS  intron 2–exon 6 Frameshift aa 99 +e +
  L-1236  MC G491A W142STOP +d +
  U-H01  NS  193–200 Frameshift aa 43 +d +
HL biopsies
  1 + NS  C2275A Q737K + +
  2 + UN G2317A E751K + +
  3 + UN   + 
  4 + LR   + 
  5 + MC G2317Rf M788I  
  6 + MC   n.e. 
  7 + NS   n.e. 
  8 + NS    
  9 + MC    
  10 + MC    
  11 + NS    
  12 + MC    
  13 + NS    
  14 + MC    
  15 + UN    
  16  NS G320A W85STOP + +
  17  NS  1,824–1,875 Frameshift aa 586 + +
  18  NS G1420T E452STOP + +
  19  UN  GG 132–133/T971C Frameshift aa 22/L302P + +
  20  NS G2323A A753T +g +
  21  NS  TGTTCAG 215–221/ C 1436 Frameshifts aa 50, 457  n.e.h
  22  NS  GTTCTCG 811–817 Frameshift aa 249  
  23  NS Ins T 992–993 Frameshift aa 309  
  24  NS  TG 1,945–1,946 Frameshift aa 627   
  25  NS  GC 1,361–1,362 Frameshift aa 432   
  26  NS   + 
  27  NS   + 
  28  NS   + 
  29  MC    
  30  NS   n.e. 
CD30+ HRS cells were analyzed in groups of 10–20 cells. In cases of mutation, TNFAIP3 was additionally sequenced from single HRS and nonneoplastic cells. cHLs were further 
tested for allelic losses using interphase cytogenetics. EBV status was determined by LMP1 immunohistochemical staining and/or EBV-encoded RNA in situ hybridization. Del, 
deletion; n.e., not evaluable; , deletion; Dupl., duplication; Ins, insertion; LR, lymphocyte rich; MC, mixed cellularity; NS, nodular sclerosis; UN, unclassifiable.
aCorresponding to GenBank/EMBL/DDBJ accession no. NM_006290.2.
bCorresponding to PDB accession no. NP_006281.
cAs indicated by interphase cytogenetics, SNP chip analysis, and/or sequence analysis. Because of the frequent hyperploidy of the HRS cells, it cannot be excluded that cases with 
diploid signal patterns in the FISH analysis also carry (subclonal) losses of the TNFAIP3 locus (from a hyperploid clone; Table S1, cases 21, 22, and 24). A high intratumoral 
variability of the signal patterns is typical for cHL. In four mutated primary cHL (cases 1, 2, 17, and 18), allelic losses were identified by the detection of only the mutated alleles. 
The latter three cases were not evaluable by interphase cytogenetics, but case 1 may harbor an uniparental disomy. In case 23, the presence of two alleles was evident from the 
concurrent detection of mutated and unmutated sequences. In cases 5, 15, and 29, presence of two alleles was evident by heterozygous constellation of polymorphisms (Fig. S2).
dLOH shown by GeneChip SNP chip analysis.
eHomozygous deletion (reference 19).
fSequence variation was also found in nontumor cells and, hence, does not represent a somatic mutation but, presumably, a polymorphism.
gSignal constellation of FISH analysis indicated biallelic loss of TNFAIP3 in a fraction of HRS cells (Table S1).
hAllelic distribution could not be determined because of the long distance of mutations on genomic DNA.JEM VOL. 206, May 11, 2009  985
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ated transcriptional activity of NF-B (Fig. 3 A). Mean tran-
scriptional reduction of these genes by A20 ranged between 
4.1- and 5.5-fold in KM-H2 and 2.5- and 6.5-fold in L-1236 
as compared with cells transduced with luciferase-expressing 
viruses, respectively. A similar decrease of transcription of 
NF-B target genes was seen in KM-H2 and L-1236 cells 
expressing IBS32,36A (mean reduction values = 6.9–9.1 for 
KM-H2 and 3.1–6.4 for L-1236). Remarkably, besides inac-
tive TNFAIP3, KM-H2 cells also harbor inactivating muta-
tions  in  NFKBIA  (IB)  (25).  In  contrast,  L-428  cells, 
strongly expressing endogenous wild-type A20, did not show 
down-regulation of NF-B transcriptional activity by A20 
gene transfer (mean = 1–1.1), indicating that this increased 
A20 expression does not impair NF-B activity in these cells. 
Notably, L-428 cells carry inactivating mutations in the NF-B 
inhibitors NFKBIA and NFKBIE (IB) (25, 26). In ac-
cordance with the known effect of A20 on RIP protein   
stability, we observed strongly reduced levels of RIP protein 
by the T2A sequence by the absence of detectable fusion 
protein (Fig. S3). The analysis also indicated that lentivirally 
transduced cells express an approximately fourfold level of 
A20  compared  with  L-428  cells,  expressing  endogenous 
wild-type A20. To investigate the consequences of reconsti-
tution of A20 in cHL cell lines, we FACS sorted 2,500 cells 
transduced with the respective lentiviruses according to GFP 
expression, and determined by quantitative PCR (qPCR) 
mRNA  levels  of  selected  NF-B  target  genes  (BIRC3, 
ICAM1, and LTA), which are negatively regulated upon in-
hibition of NF-B in cHL (2). qPCR values of NF-B target 
genes were normalized to GAPDH, and the resulting data 
from luciferase-expressing cells, which served as negative 
control, were subtracted from A20- and IBS32,36A-trans-
duced cells (Ct method). Upon reconstitution of A20   
in cell lines carrying inactivated TNFAIP3 (KM-H2 and   
L-1236), we observed a significant decrease of mRNA levels of 
the selected NF-B target genes, indicating a globally attenu-
Figure 2.  Chromosomal deletion of TNFAIP3 in cHL detected by interphase cytogenetics. FICTION analyses of representative cHL cases combining 
CD30 expression (red) and FISH probes for TNFAIP3 and chromosome 6 centromere (blue [b]). In the double-color assays in A–C and E and F, the TNFAIP3 
probe is labeled in green (g); in the triple-color assay applied in D, the TNFAIP3 probe gives a g/orange colocalized (co) signal. Two different strategies are 
used to display double- and triple-color FISH assays in combination with CD30 immunofluorescence; i.e., double-color assays (A–C and E and F) are shown 
using a triple-color display, whereas a false multicolor display as obtained by Isis software is applied for the triple-color assay (D) to simultaneously show 
four colors (i.e., CD30 [r], TNFAIP3 [g] and orange, and chromosome 6 centromere [b]). In contrast to the triple-color assay, the quadruple-color assay is 
based on the overlay of two displays generated by Isis software. To this end, the different channels needed to be individually enhanced so that the final 
integrated image shows multicolor signals. Fluorescent signals are shown in a false-color display. Arrows point to CD30+ HRS cells. For each case, between 
6 and 26 evaluable HRS cells (mean = 12) were considered. (A) HRS cell (case 41) with normal diploid signal pattern (2g + 2b). (B) HRS cell (case 36) exhib-
iting one copy of TNFAIP3 (1g) and three copies of chromosome 6 centromere (3b), indicating the presence of a chromosomal deletion of TNFAIP3. (C) HRS 
cell (case 16) exhibiting one copy of TNFAIP3 (1g) and two copies of chromosome 6 centromere (2b), indicating the presence of a chromosomal deletion of 
TNFAIP3. (D) HRS cell (case 19) exhibiting one copy of TNFAIP3 (1co) and three copies of chromosome 6 centromere (3b), indicating the presence of a 
chromosomal deletion of TNFAIP3. (E) HRS cell (case 35) exhibiting two copies of TNFAIP3 (2g) and three copies of chromosome 6 centromere (3b), indicat-
ing the presence of a chromosomal deletion of TNFAIP3. (F) HRS cell (case 33) lacking signals for TNFAIP3 (0g) but showing two copies of chromosome  
6 centromere (2b), indicating the presence of a chromosomal (homozygous?) deletion of TNFAIP3. Neighboring bystander CD30 cells mostly show normal 
signal patterns (2g or 2co + 2b), although truncation artifacts do occur (some signals are out of the focus plane). Bars, 10 µm.986 INACTIVATION OF TNFAIP3 (A20) IN cHL AND PMBL | Schmitz et al.
findings to verify this hypothesis. The chromosomal region 
containing TNFAIP3 is recurrently affected by monoallelic 
deletions in different lymphomas and the fact that, in follicular 
lymphoma for example, which is not characterized by strong 
NF-B activity, monoallelic deletions including TNFAIP3 
were found, but no somatic mutations within the gene in 50 
cases analyzed (14), indicated that another gene is the target 
of the deletions in follicular lymphoma.
The striking clustering of unequivocally destructive mu-
tations with EBV cases of cHL defines the first example of 
a genetic lesion that distinguishes EBV+ from EBV cHL 
cases. This clustering suggests complementing functions of 
A20 inactivation and EBV transformation, and thereby sup-
ports important pathogenetic roles of both events. On the 
other hand, there is also indication from the cHL cell lines 
that multiple transforming events in the NF-B pathway can 
cooperate, such as concurrent TNFAIP3 and NFKBIA mu-
tations in KM-H2. This represents one of the few examples 
in which multiple genetic lesions occur in the same path-
way in one tumor clone. Whether concurrent mutations in   
TNFAIP3 and NFKBIA, which is mutated in 10–20% of cHL 
cases (25, 27, 28), also occur in primary cases of cHL remains 
to be identified. In PMBL, NFKBIA mutations have not 
been found (29). The important role of A20 as a key regula-
tor of NF-B activity in multiple immune functions was re-
cently impressively demonstrated (8, 30, 31), and its role as a 
in A20-reconstituted L-1236 cells as compared with nonre-
constituted L-1236 cells (Fig. S4).
A20 reconstitution confers cytotoxicity  
to A20-deficient cHL cell lines
To test the consequence of A20 reconstitution on prolifera-
tion and/or survival in A20-negative cell lines, we performed 
an MTS assay with sorted GFP+ cells expressing either A20, 
IBS32,36A, or luciferase. This revealed a strong cytotoxic ef-
fect of A20 reexpression in L-1236 cells and a more moderate 
one in KM-H2 cells compared with the luciferase-expressing 
negative control cells (Fig. 3 B). In contrast, overexpression 
of A20 in L-428 cells had little or no effect on these cells (also 
indicating that the experimental overexpression of A20 per se 
is  not  cytotoxic),  whereas  IBS32,36A  expression  showed 
strong cytotoxicity (Fig. 3 B and Fig. S5).
Concluding remarks
We identify TNFAIP3 as a novel tumor suppressor gene in 
cHL and PMBL by showing frequent somatic and clonal bi-
allelic inactivation of the gene, and presenting evidence that 
loss of A20 function contributes to the constitutive activity of 
the transcription factor NF-B and the survival and/or pro-
liferation of the cells. The detection of destructive somatic 
mutations within the gene and frequent complete inactiva-
tion, together with the functional data, are indeed critical 
Table II.  Sequence analysis of TNFAIP3 from primary PMBLs and cell line Karpas-1106P
Sample Nucleotide changea Amino acid changeb Both alleles 
mutated
Cell line
  Karpas-1106P  TCATC 1,037–1,041c Frameshift aa 324 +
Biopsies
  1  AG 1,294–1,295c Frameshift aa 410 +
  2 C635M/ CAGAGAAAACAAA 1,959–1,971 + 8 bp  
     (splice donor site)d
S190STOP/frameshift aa 631 +
  3 Ins A389/T2382K/A2409W/T2437Y/A2439R Frameshift aa 108/N772K/E781D/STOP>Q/STOP>Q n.e.e
  4 T1070Y L335STOP 
  5   
  6   
  7   
  8   
  9   
  10   
  11   
  12   
  13   
Analysis was performed on whole-tissue section DNA. , deletion; Ins, insertion.
aCorresponding to GenBank/EMBL/DDBJ accession no. NM_006290.2.
bCorresponding to PDB accession no. NP_006281.
cLOH as indicated by sequence analysis; in Karpas-1106P and one mutated primary PMBL (case 1), allelic losses were identified by the detection of only the mutated 
alleles (Fig. S2 C).
dMutations on separate alleles as indicated by cloning of PCR product spanning both sites of mutations.
eFour missense mutations (at positions 2,382–2,438) located on one allele, as indicated by cloning. Because of the long distance between the insertion (position 389) and 
missense mutations (positions 2,382–2,438) on genomic DNA, allelic distribution of insertion and missense mutations could not be determined.JEM VOL. 206, May 11, 2009  987
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immunohistochemical staining and/or EBV-encoded RNA in situ hybridization. 
PMBLs were obtained from the Institute of Pathology at the University of Hei-
delberg and the Department of Pathology at the University of Kiel. PMBL cell 
line Karpas-1106P and cHL cell lines L-428, L-591, L-1236, HDLM-2, KM-H2, 
and the recently established line U-HO1 (33) were analyzed. Approval by the In-
stitutional Review Boards in Kiel and Frankfurt was obtained for these studies.
Laser microdissection and pressure catapulting of HRS and nontu-
mor cells. 5-µm frozen lymph node sections of primary cHL biopsies were 
mounted  on  membrane-covered  slides  (PALM)  and  stained  with  anti-
CD30 antibody (BerH2; Dako). Single CD30+ HRS cells were microdis-
sected using laser microdissection and pressure catapulting (PALM) into 
PCR buffer, and pooled into groups of 10–20 cells. Nonneoplastic cells 
were microdissected in groups of 20–50 cells.
tumor suppressor gene may well go beyond cHL and PMBL, 
as shown by the recent detection of TNFAIP3 mutations in 
marginal zone B cell lymphomas (32).
MATERIALS AND METHODS
Patient samples and cell lines. Lymph node samples from 54 patients with 
cHL were collected from the Department of Pathology, Hematopathology Sec-
tion and Lymph Node Registry at the University of Kiel and the Senkenberg In-
stitute of Pathology at the University of Frankfurt. According to morphological 
and immunohistochemical criteria, 26 cases were classified as nodular sclerosis 
cHL, 20 cases were classified as mixed cellularity, 1 case was classified as lympho-
cyte depleted, 1 case was classified as lymphocyte rich, and 6 cases were unclassi-
fied.  In  cases  for  sequence  analysis,  EBV  status  was  determined  by  LMP1 
Figure 3.  A20 reconstitution in cHL cell lines harboring inactivating TNFAIP3 mutations results in reduction of transcriptional NF-B ac-
tivity and reduction of cellular metabolism. cHL cell lines harboring inactive TNFAIP3 (L-1236 and KM-H2) or wild-type TNFAIP3 (L-428) were lentivi-
rally transduced with expression constructs encoding the reporter GFP and either A20, IBS32,36A superrepressor or luciferase as control (Ctrl). (A) GFP+ 
cells were analyzed by qPCR for expression of representative NF-B target genes (BIRC3, ICAM1, and LTA). Reduction of NF-B target gene expression 
upon TNFAIP3 or IBS32,36A gene transfer was determined by subtraction of Cts of luciferase-expressing cells, respectively (Ct method). Bars repre-
sent mean values of down-regulation resulting from at least three independent infections that were each analyzed in several independent replicates.  
p-values were calculated per gene using the Wilcoxon rank-sum test to determine the level of significance between negative regulation of NF-B target 
genes in L-1236 and KM-H2 cells in comparison to L-428 cells in response to A20 expression. (B) GFP+ cells were FACS sorted, cultured for 48 h, and  
analyzed by MTS assay for metabolic activity. Mean OD values, reflecting conversion of MTS into a formazan product, are normalized to the empty medium 
control. The quantity of formazan product as measured by the amount of 490-nm absorbance is directly proportional to the number of living cells in 
culture. The experiments were performed in duplicates (Fig. S5). Each value is based on four measurements.988 INACTIVATION OF TNFAIP3 (A20) IN cHL AND PMBL | Schmitz et al.
Biosystems). For each cell line, transfections and sorting of cells were done at 
least in triplicates, of which mostly three or four independent qPCR measure-
ments were performed.
MTS assay. cHL cell line cells were FACS sorted 80 h after infection in ali-
quots of 10,000 GFP-expressing cells in PBS/0.5% BSA. After centrifuga-
tion, the aliquots were resuspended in 100 µl of conditioned culture medium 
each in a 96-well plate. After 48 h, CellTiter 96 AQueous One Solution re-
agent (Promega) was added to each well and analyzed at 490 nm. The con-
version of MTS into a formazan product was accomplished by dehydrogenase 
enzymes found in metabolically active cells. The quantity of formazan prod-
uct as measured by the amount of 490-nm absorbance is directly proportional 
to the number of living cells in culture.
Online supplemental material. Genome-wide human SNP Array 6.0 
analyses of cHL cell lines revealing deletions and LOH at the TNFAIP3 
locus are shown in Fig. S1. Fig. S2 exemplifies TNFAIP3 sequences of pri-
mary HRS cells, PMBLs, and corresponding nontumor cells. Expression 
and function of the A20-T2A-GFP lentiviral construct is shown in Fig. S3. 
Fig. S4 shows reduction of RIP protein levels upon A20 reexpression in   
L-1236 cells. Additional data on A20 reconstitution in cHL cell lines harboring 
inactivating TNFAIP3 mutations are depicted in Fig. S5. Table S1 provides 
detailed results of the interphase cytogenetic analyses. Table S2 shows primer 
sequences used for seminested two-round genomic DNA amplification of 
TNAIP3.  Online  supplemental  material  is  available  at  http://www.jem 
.org/cgi/content/full/jem.20090528/DC1.
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